A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Summary

The present trial will use an open label design to investigate the effect of BI 144807 on central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD patients. A further objective is to collect data on adverse events, vital signs, ECG and clinical laboratory parameters of BI 144807 in the same patient group.

Timeline

Start

2014-06

Primary completion

2015-03

Completion

2015-04

Drugs

Indications